{
    "clinical_study": {
        "@rank": "72403", 
        "brief_summary": {
            "textblock": "To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii\n      pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4\n      lymphocytes per mm3. To determine whether the long-term toxicities associated with daily\n      dapsone in this population are tolerable."
        }, 
        "brief_title": "Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)", 
        "condition": [
            "Pneumonia, Pneumocystis Carinii", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "AIDS-Related Complex", 
                "Pneumonia", 
                "Pneumonia, Pneumocystis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        The patient must have HIV positive antibody test and presence of oral thrush or hairy\n        leukoplakia.\n\n          -  Patient must be willing and able to sign informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.\n\n          -  Prophylaxis for PCP in preceding 3 months.\n\n          -  Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.\n\n          -  Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative\n             dermatitis during treatment with dapsone.\n\n          -  History of poor compliance.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT).\n\n        Patients with the following are excluded:\n\n          -  Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.\n\n          -  Prophylaxis for PCP in preceding 3 months.\n\n          -  Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.\n\n          -  Concurrent or prior therapy with zidovudine (AZT).\n\n          -  Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative\n             dermatitis during treatment with dapsone.\n\n          -  History of poor compliance.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Zidovudine (AZT)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002043", 
            "org_study_id": "007B"
        }, 
        "intervention": {
            "intervention_name": "Dapsone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dapsone"
        }, 
        "keyword": [
            "AIDS-Related Opportunistic Infections", 
            "Pneumonia, Pneumocystis carinii", 
            "Leukoplakia, Oral", 
            "Dapsone", 
            "AIDS-Related Complex", 
            "Candidiasis, Oral"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90095"
                }, 
                "name": "UCLA CARE Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002043"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jacobus Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 1989"
    }, 
    "geocoordinates": {
        "UCLA CARE Ctr": "34.052 -118.244"
    }
}